The document provides information about the 8th Asia Generics Conference taking place from 11-14 November 2013 in Singapore. The conference will discuss topics related to developing competitive strategies for pricing, portfolio management, and market access in the generics industry in Asia. It outlines an agenda with sessions on market outlook, regulatory pathways, market access opportunities, product differentiation, branding, distribution, and strategic partnerships. Speakers include representatives from Johnson & Johnson, Pfizer, Unilab, and other pharmaceutical companies. Workshops on go-to-market innovation and biosimilars entry are also advertised.
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will Be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India. Please find the detailed agenda for the same with this email.
FMD:- + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
Utilizing the powerful impact of real-time information on drug development an...Merlien Institute
Utilizing the powerful impact of real-time information on drug development and new product launch
Janet Kosloff - Co-Founder & CEO - InCrowd
Matt Grimley - Senior Market Research Manager - Vertex Pharmaceuticals
Determining the key challenges facing commercial organizations when launching a new drug. Evaluating the information needs related to pre-launch, activity product launch and immediate post launch. Utilizing innovative mobile technology for providing real-time access of valuable insights from target audience.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Greetings from Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will Be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India. Please find the detailed agenda for the same with this email.
FMD:- + 91 9171350244 or deepak@virtueinsight.co.in, deepakrajvirtueinsight@gmail.com
Utilizing the powerful impact of real-time information on drug development an...Merlien Institute
Utilizing the powerful impact of real-time information on drug development and new product launch
Janet Kosloff - Co-Founder & CEO - InCrowd
Matt Grimley - Senior Market Research Manager - Vertex Pharmaceuticals
Determining the key challenges facing commercial organizations when launching a new drug. Evaluating the information needs related to pre-launch, activity product launch and immediate post launch. Utilizing innovative mobile technology for providing real-time access of valuable insights from target audience.
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
This is my Keynote presentation to Pharma Forum Russia, St. Petersburg, May 23rd, 2013.
It gives an outline of crucial elements in building a new market approach to different markets.
Pharmaceutical companies spend nearly 97 percent of their marketing budgets to capture initial market share.
Since the majority of spend goes towards attracting new consumers, efforts at retaining existing customers are given short shrift, with a paltry three percent of budgets. By focusing exclusively on new customers, companies are missing a valuable opportunity to increase sales and market share.
Pharmaceutical companies can no longer ignore the hidden value available by increasing patient adherence. Today, an estimated 70 percent of patients who begin a Pharmaceutical therapy discontinue it within 1 year, even those with chronic conditions that require ongoing treatment or those taking chemotherapy to prevent cancer recurrence. This costs the global Pharmaceutical Industry an estimated $30 Billion a year.
Put another way, increased adherence for a product with approximately $1 Billion in sales would translate to an additional $30 to $40 Million in annual revenue. In addition, since it costs six times more to attract new patients than to retain current patients, increasing the focus on, and yields from, adherence means additional money saved and earned.
Companies who implement strategies to increase adherence and persistence with their products can better face the numerous challenges in today’s market, and increase their share of profits.
But how does a company even begin? In this report we look at the formidable barriers Pharma companies face in improving adherence, elements of successful adherence programs and methods for ensuring the best ROI.
How to Properly Deploy the iPad Within the Pharma Sales ForceCognizant
Pharmaceuticals companies are deploying adopting mobility solutions, especially Apple's iPad, for their sales staff, with benefits including enhanced detailing, cost savings, better targeted presentations, and much more. We outline a holistic strategy for adopting pharma mobility for an array of sales and marketing activities.
Greeting From Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India.
KEY SPEAKERS:-
• V. Kalaiselvan, Principal Scientific Officer, Indian Pharmacopoeia Commission Ministry of Health and Family Welfare Govt. of India
• Arun Bhatt, President, ClinInvent Research
• Deepa Arora, Vice President - Pharmacovigilance & Global Head - Drug Safety & Risk Management, Lupin
• Bhaswat Chakraborty, Senior Vice President, Cadila
• Babita Kirodian, Head of Country Pharmacovigilance, Bristol Myers Squibb
• Nipom Deka, Regional Pharmacovigilance Manager, Asia, Africa & Middle East, Abbott
• Shashidhar Swamy, Head Pharmacovigilance, Wockhardt
• Mohammad Salim, Country Safety Lead, Pfizer
• Manish Verma, Director Medical Affairs, Sanofi
• Karthik Babu, Affiliate Pharmacovigilance Head, Sanofi
• Chirag Trivedi, Director & Head of Clinical Study Unit, Sanofi
• Priya Chatterjee, Director - Regulatory Affairs, Merck Serono
• Milind Antani, Partner In-Charge - Pharma LifeSciences, Nishith Desai Associate
• Anand Harugeri, Patient Safety and Regulatory Affairs Manager, Astrazeneca
• Deepti Sanghavi, Assistant Manager - Medical Writing, Tata Consultancy Services
• Sandeep Sewlikar, Manager – Clinical Affairs, Johnson and Johnson
• Girish Parhate, Head Regulatory Affairs, Bayer Pharmaceuticals
• Rajashri Survase Ojha, Founder and MD, Raaj GPRAC
• Vandana Jolad, Director, VIaTal Pharma
Plus Many More...
CONFERENCE BOOKING DETAILS:-
• Early Bird Discounted Price - Conference Delegate Pass (INR 6,000 + Tax (14%) per delegate) - Book and Pay before 20th July 2015 avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Standard Price after Early Bird Discounted Time – 1 or 2 Delegates (INR 7,000 + Tax (14%) per delegate) - You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Group Discounts – 3 or 4 Delegates - (INR 6,500 + Tax (14%) per delegate)
• Group Discounts – 5 or more Delegates - (INR 5,000 + Tax (14%) per delegate)
• Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to TEL: +91 44 65515695, +91 9940043915 or swetha@virtueinsight.co.in
In case you or any of your colleagues might be interested in participating in the same, please let me know and I will be happy to call you and help you with the registration.
Thank you for your time and consideration. I look forward to hearing from you
Thanks,
Swetha
The 10 Companies Booming in Healthcare Sectorinsightscare
Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”. This edition portrays the inspiring stories of the listed pre-eminent organizations that are shaping the future of healthcare through innovation and dedication.
Prophet 2014 Healthcare Exchange Consumer Study ResultsProphet
Eight million people signed up for insurance plans via public exchanges in the first year of the Affordable Care Act, yet an estimated 40+ million still remain uninsured. When annual enrollment opens again in October, how should companies change their tactics and targets based on experiences in year one? It’s time to learn from year one, and plan for year two and beyond.
We've released our findings from our 2014 survey of consumer attitudes and experiences with the Affordable Care Act’s first healthcare exchange open enrollment period. The survey of 1000 American adults shows that while nearly half of respondents plan to purchase healthcare on the exchange in the future, concerns over cost, confusion over subsidies and general distrust of health insurance companies persist.
To hear the audio that accompanies these slides, watch a recording of our webinar here: http://bit.ly/1vbOvUO.
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Kuheli Roy
The new product planning function within bio-pharmaceutical companies is tasked with the challenging role of delivering potential new products in shorter time frames and minimum development costs.
This Best Practices, LLC benchmarking report examines the role and impact of new product planning function on product commercialization. In particular, it examines the impact of structure, resources and activities of new product planning groups on product commercialization.
Download Full Report: http://bit.ly/2e8ErMD
The SSG Wellness SpectrumTM powered by GfK MRI sheds light on key planning issues.
Which consumers will be most responsive to ‘new & improved’ healthy and green offerings? Which consumers are compromising wellness? Which consumers rather indulge? How brands rank in consumers’ wellness spectrum? SSG will illustrate the upside potential of more effective targeting, messaging and path to purchase through an actionable Total Market insights approach
Building your life sciences business in Europe, North America and Internationally
The Solution
Bridgehead provides a coordinated, professionally managed strategy to retain value, whilst minimising risk. Bridgehead is the only Boston, London and Zug based group providing an integrated healthcare solution for launch into European and US markets. Bridgehead coordinates proven, experienced, Professional service providers, who have US and European experience in all of the essential launch and support components.
The importance of getting a Biotechnology launch right the first time and the difficulty of recovering from a slow sales trajectory suggest that there is a need to evolve the go-to-market approach to ensure launch success. Successfully bringing a product to market has been increasingly difficult as the U.S. Healthcare Market has evolved since implementation of the Affordable Care Act. Pricing has become more controlled - and value based - as healthcare costs have increased to an unsustainable level. Customers realize there is little product differentiation and the traditional Field Sales representative based go-to-market models are struggling to effectively communicate the value proposition to more demanding and informed customers and stakeholders. The results of our pre-launch survey are provided here along with recommendations for what Biotechnology companies can do to improve launch readiness.
Pharma Policy 2017 - Read it in MedicinMan September 2017 IssueAnup Soans
1. Draft Pharma Policy: The Good, The Bad and The Ugly...............................................1
Interview with Sunil Attavar
2. Career Brand Plan: A Career Stepping
Stone..........................................................9
Soham Wagh
3. Succeeding as Country GM at GSK: A Whitepaper..............................................12
Sundar Ramachandran
4. Role of Digital in the Customer Journey ....................................................................21
Salil Kallianpur
5. Executive Function Disorder .................24
Vivek Hattangadi
Intervención de Kepa Solaun, Director de Factor CO2 en el marcos de las Jornadas de mercados de carbono.
17_02_2011
Evento relacionado
http://www.eoi.es/portal/guest/evento/1393/
This is my Keynote presentation to Pharma Forum Russia, St. Petersburg, May 23rd, 2013.
It gives an outline of crucial elements in building a new market approach to different markets.
Pharmaceutical companies spend nearly 97 percent of their marketing budgets to capture initial market share.
Since the majority of spend goes towards attracting new consumers, efforts at retaining existing customers are given short shrift, with a paltry three percent of budgets. By focusing exclusively on new customers, companies are missing a valuable opportunity to increase sales and market share.
Pharmaceutical companies can no longer ignore the hidden value available by increasing patient adherence. Today, an estimated 70 percent of patients who begin a Pharmaceutical therapy discontinue it within 1 year, even those with chronic conditions that require ongoing treatment or those taking chemotherapy to prevent cancer recurrence. This costs the global Pharmaceutical Industry an estimated $30 Billion a year.
Put another way, increased adherence for a product with approximately $1 Billion in sales would translate to an additional $30 to $40 Million in annual revenue. In addition, since it costs six times more to attract new patients than to retain current patients, increasing the focus on, and yields from, adherence means additional money saved and earned.
Companies who implement strategies to increase adherence and persistence with their products can better face the numerous challenges in today’s market, and increase their share of profits.
But how does a company even begin? In this report we look at the formidable barriers Pharma companies face in improving adherence, elements of successful adherence programs and methods for ensuring the best ROI.
How to Properly Deploy the iPad Within the Pharma Sales ForceCognizant
Pharmaceuticals companies are deploying adopting mobility solutions, especially Apple's iPad, for their sales staff, with benefits including enhanced detailing, cost savings, better targeted presentations, and much more. We outline a holistic strategy for adopting pharma mobility for an array of sales and marketing activities.
Greeting From Virtue Insight,
I am happy to invite you and your colleagues to be a sponsor/ delegate for our upcoming “9th Pharmacovigilance 2015” The conference will be held on 2nd September 2015, Kohinoor Continental Hotel, Mumbai, India.
KEY SPEAKERS:-
• V. Kalaiselvan, Principal Scientific Officer, Indian Pharmacopoeia Commission Ministry of Health and Family Welfare Govt. of India
• Arun Bhatt, President, ClinInvent Research
• Deepa Arora, Vice President - Pharmacovigilance & Global Head - Drug Safety & Risk Management, Lupin
• Bhaswat Chakraborty, Senior Vice President, Cadila
• Babita Kirodian, Head of Country Pharmacovigilance, Bristol Myers Squibb
• Nipom Deka, Regional Pharmacovigilance Manager, Asia, Africa & Middle East, Abbott
• Shashidhar Swamy, Head Pharmacovigilance, Wockhardt
• Mohammad Salim, Country Safety Lead, Pfizer
• Manish Verma, Director Medical Affairs, Sanofi
• Karthik Babu, Affiliate Pharmacovigilance Head, Sanofi
• Chirag Trivedi, Director & Head of Clinical Study Unit, Sanofi
• Priya Chatterjee, Director - Regulatory Affairs, Merck Serono
• Milind Antani, Partner In-Charge - Pharma LifeSciences, Nishith Desai Associate
• Anand Harugeri, Patient Safety and Regulatory Affairs Manager, Astrazeneca
• Deepti Sanghavi, Assistant Manager - Medical Writing, Tata Consultancy Services
• Sandeep Sewlikar, Manager – Clinical Affairs, Johnson and Johnson
• Girish Parhate, Head Regulatory Affairs, Bayer Pharmaceuticals
• Rajashri Survase Ojha, Founder and MD, Raaj GPRAC
• Vandana Jolad, Director, VIaTal Pharma
Plus Many More...
CONFERENCE BOOKING DETAILS:-
• Early Bird Discounted Price - Conference Delegate Pass (INR 6,000 + Tax (14%) per delegate) - Book and Pay before 20th July 2015 avail the early bird discounted price. You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Standard Price after Early Bird Discounted Time – 1 or 2 Delegates (INR 7,000 + Tax (14%) per delegate) - You can simply email or call and book your conference delegate seats on TEL: +91 9940043915. Email – swetha@virtueinsight.co.in
• Group Discounts – 3 or 4 Delegates - (INR 6,500 + Tax (14%) per delegate)
• Group Discounts – 5 or more Delegates - (INR 5,000 + Tax (14%) per delegate)
• Conference Sponsor & Exhibition Stall - Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to TEL: +91 44 65515695, +91 9940043915 or swetha@virtueinsight.co.in
In case you or any of your colleagues might be interested in participating in the same, please let me know and I will be happy to call you and help you with the registration.
Thank you for your time and consideration. I look forward to hearing from you
Thanks,
Swetha
The 10 Companies Booming in Healthcare Sectorinsightscare
Acknowledging the remarkable contribution of the leading companies in the care sector, we bring to you the special issue of “The 10 Companies Booming in Healthcare Sector”. This edition portrays the inspiring stories of the listed pre-eminent organizations that are shaping the future of healthcare through innovation and dedication.
Prophet 2014 Healthcare Exchange Consumer Study ResultsProphet
Eight million people signed up for insurance plans via public exchanges in the first year of the Affordable Care Act, yet an estimated 40+ million still remain uninsured. When annual enrollment opens again in October, how should companies change their tactics and targets based on experiences in year one? It’s time to learn from year one, and plan for year two and beyond.
We've released our findings from our 2014 survey of consumer attitudes and experiences with the Affordable Care Act’s first healthcare exchange open enrollment period. The survey of 1000 American adults shows that while nearly half of respondents plan to purchase healthcare on the exchange in the future, concerns over cost, confusion over subsidies and general distrust of health insurance companies persist.
To hear the audio that accompanies these slides, watch a recording of our webinar here: http://bit.ly/1vbOvUO.
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Kuheli Roy
The new product planning function within bio-pharmaceutical companies is tasked with the challenging role of delivering potential new products in shorter time frames and minimum development costs.
This Best Practices, LLC benchmarking report examines the role and impact of new product planning function on product commercialization. In particular, it examines the impact of structure, resources and activities of new product planning groups on product commercialization.
Download Full Report: http://bit.ly/2e8ErMD
The SSG Wellness SpectrumTM powered by GfK MRI sheds light on key planning issues.
Which consumers will be most responsive to ‘new & improved’ healthy and green offerings? Which consumers are compromising wellness? Which consumers rather indulge? How brands rank in consumers’ wellness spectrum? SSG will illustrate the upside potential of more effective targeting, messaging and path to purchase through an actionable Total Market insights approach
Building your life sciences business in Europe, North America and Internationally
The Solution
Bridgehead provides a coordinated, professionally managed strategy to retain value, whilst minimising risk. Bridgehead is the only Boston, London and Zug based group providing an integrated healthcare solution for launch into European and US markets. Bridgehead coordinates proven, experienced, Professional service providers, who have US and European experience in all of the essential launch and support components.
The importance of getting a Biotechnology launch right the first time and the difficulty of recovering from a slow sales trajectory suggest that there is a need to evolve the go-to-market approach to ensure launch success. Successfully bringing a product to market has been increasingly difficult as the U.S. Healthcare Market has evolved since implementation of the Affordable Care Act. Pricing has become more controlled - and value based - as healthcare costs have increased to an unsustainable level. Customers realize there is little product differentiation and the traditional Field Sales representative based go-to-market models are struggling to effectively communicate the value proposition to more demanding and informed customers and stakeholders. The results of our pre-launch survey are provided here along with recommendations for what Biotechnology companies can do to improve launch readiness.
Pharma Policy 2017 - Read it in MedicinMan September 2017 IssueAnup Soans
1. Draft Pharma Policy: The Good, The Bad and The Ugly...............................................1
Interview with Sunil Attavar
2. Career Brand Plan: A Career Stepping
Stone..........................................................9
Soham Wagh
3. Succeeding as Country GM at GSK: A Whitepaper..............................................12
Sundar Ramachandran
4. Role of Digital in the Customer Journey ....................................................................21
Salil Kallianpur
5. Executive Function Disorder .................24
Vivek Hattangadi
Intervención de Kepa Solaun, Director de Factor CO2 en el marcos de las Jornadas de mercados de carbono.
17_02_2011
Evento relacionado
http://www.eoi.es/portal/guest/evento/1393/
Presentación breve del TDAH .
Inicio, lo que es, datos importantes, sintomatología, impacto psicosocial, la familia y el TDAH, lo que requieren los niños, instituciones a dónde acudir y sugerencias bibliogarficas
Here's some of what it covers:
Mobile context
Mobile testing tools
Fixed vs. fluid layouts
Scalable layouts
Horizontal layouts
Designing for touch
Real-time content
La formación profesional en la especializacion inteligente de las regionesOrkestra
1. El por qué de las estrategias de especialización inteligente
1.1. Del modelo lineal a los sistemas de innovación
1.2. Las estrategias de especialización inteligente
Los centros de FP y las prioridades verticales
Los centros de FP y las prioridades horizontales
3.1. La FP inicial
3.2. La FP para el empleo
3.3. Otras funciones no tradicionales: prestación de servicios, emprendimiento, y cooperación y desarrollo territorial
4. Resumen y conclusiones
A successful generic product starts with understanding consumer needs and brand value. On November 4-7 in Singapore, IBC will host the 9th Annual Generics Asia 2014, Asia’s longest running Generics conference, to help you and your organization understand how to incorporate marketing and partnership into your business strategy.
The key topics to be covered at the event include:
Regulatory Update and Accelerating Access to New market
o A panel of experts from Philippines Chamber of Pharmaceutical Industry, Actavis, Hovid and Pfizer
Building Brand Awareness and Delivering New Products with a Cost Effective Strategy
o Allan Marx Ancheta, Director Business Development and Strategy, Commercial Innovation and Alliance, Merck
Managing Sale Force Effectiveness and Innovative Channels for Generics Products
o Marvin Biliwang, Commercial Effectiveness Director, Takeda Pharmaceuticals
Establishing Partnerships to Add Value and Build Market Share
o Philip Cox, President Director, PT Takeda Indonesia
Innovative Models and Super Generics for Prolonging Product Life Cycles
o Dr. Shirish Kulkarni, Senior Vice President, Formulation Development, Sun Pharmaceutical
OTC Pharma Asia is the ONLY regional OTC and health supplement marketing conference in Asia, featuring success stories from Heads of OTC, health supplements and consumer health marketers from across the region.
IBC’s OTC Pharma Asia conference is returning 2-5 March 2015 at Grand Copthorne Waterfront Hotel, Singapore to prepare you for future growth in the OTC and Consumer Health market in Asia. You will witness how the OTC landscape varies by country as well as the latest product trends, consumer insights and innovative offerings in OTC – a crucial element to achieve global success.
http://www.otcpharmaasia.com
The 8th Health Insurance Asia provides a platform to discuss business potential in emerging markets (Indonesia, Vietnam, Philippines & more), updates in regulations, effective marketing, insurance product innovation, claims management & effective partnerships with stakeholders.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
Practice Areas: New Product Planning, Business Development and Licensing, Commercial Strategy and Analytics, and Epidemiology and Forecasting.
Our boutique expertise is focused on elucidating patient benefits of bio-pharmaceutical products, medical devices, and businesses. With insightful strategies and solutions aimed at planning and growing our clients’ business, our mission is to continue being the “go-to” firm and preferred partner for our clients in their commercial planning and R&D initiatives.
Our chief operating principle is an unsurpassable commitment to quality and our philosophy has been to develop and sustain strong long-term relationships with clients based on an in-depth understanding of client needs, rigorous research, sound methodologies, and keeping ahead of industry developments.
Innovative Marketing Practices for Optimization in Selected Pharmaceutical In...iicecollege
Pharmaceutical Industry is regulated by the production, distribution, selling and the marketing of the products or services which directly or indirectly includes medical, diagnostic and healthcare.It is regulated by economical, political and administrative authority to manage at all levels. So, the industry is governed by both the public and private sector. Therefore innovation is done in various pharma stakeholder and is needed in chronic and acute therapeutic segment.
For more details please visit
www.iicecollege.com
We are driven by a passionfor transforming products into brands and patients into survivors. Navicor is a 100% healthcare-focused, full-service agency that understands the unique aspects of the oncology marketplace. We have extensive oncology launch experience and have partnerships with large and small pharma and biotech companies.
Indian Medical Advisors Summit 2014 HighlightsAnup Soans
INMAS - Indian Medical Advisors Summit is first of its kind initiative that has been
undertaken in India for the cause of Medical Affairs.
INMAS - Indian Medical Advisors Summit - 2014 - Watch Video on
www.youtube.com - https://www.youtube.com/watch?v=vCNVUlzyEpg
Medical Device Asia Conference, 28-31 Oct 2014, SingaporeLei Ching Y.
MED DEVICE ASIA is the only high level platform in Asia to showcase innovative ideas, trends in partnerships with public sector and clinicians and to network with experts and industry leaders to find out about regulatory updates, investment opportunities, product development and market access.
The World Congress Summit - Leverage EHRs for Prescriber EngagementWorldCongress
This World Congress EHR Summit focuses on improving patient access by focusing on Health Information Technology and Health Information Management since the demand for Personal Health Management and Health Information Exchanges through ePrescribing and EHR portals has increased. Leverage Federal Quality Initiatives by supporting Meaningful Use through Electronic Health Records (EHRs)
Factors to keep in mind when you’re considering cloud storage services.Rita Barry
Cloud storage is a broad term. It can encompass anything from on premise solutions, to le storage, disaster recovery and off premise options. To narrow the scope, I’ve dedicated the focus of today’s discussion to the more popular cloud storage services—such as Dropbox, Box, OneDrive—which are also known as hosted, off premise solutions.
Unlike more tangible technologies where a failed implementation causes a down network, SIEM (security information and event management) requires a more qualitative approach to determining success or failure. The surprising reality is that most SIEM projects completely fail to deliver any discernable bene ts to the organization and are abandoned in frustration
www.rkon.com
Carve-outs and Mergers and Acquisitions place unique demands on IT. How can y...Rita Barry
Mergers are complex and Carve-outs only add to the dif culty and the level of complexity that the delivery team must manage. The creation of a stand-alone entity in a matter of weeks is daunting; moreover, the lack of cooperation from the legacy organization or the attrition of employees creates a chaotic environment that must be overcome. RKON helps clients to determine the most favorable level of IT sourcing and to implement the most appropriate technology for the new business unit — all to ensure a successful “day one.”
Tertiary Hospital Services Asia 2015, part of the Asia Healthcare Summit, will examine successful case studies on achieving top financially performing healthcare organizations whilst delivering quality tertiary healthcare services.
Top Industry Issues to Be Discussed Include:
Benchmarks and lessons from World Class Tertiary Hospitals
Insights on clinical and operational excellence
Investment in Tertiary Hospital Services and achieving financial success
Streamlining outpatient services
Advanced consultative care & remote monitoring of patient health
Latest technology transforming patient accessibility, care and experiences
Keynote representatives and decision makers from more than 15 public and private hospitals across the Asia Pacific region will convene and share their perspectives in developing world class tertiary hospital services, including:
Chan Choo Lin, Director of Operations, Johns Hopkins, Singapore
Dr. Alejandro C. Dizon, Chief Quality Officer, St. Luke's Medical Center, Philippines
Alastair Mah, Chief Medical Officer, University Hospital Geelong & Barwon Health, Australia
Haji Abdul Aziz Abdul Rahman, CEO, KPJ Penang Specialist Hospital, Malaysia
Seemant Jauhari, CEO, Research & Innovations, Apollo Hospitals, India
Nguyen Thi Le Thu, Marketing & Business Development Director, FV Hospital, Vietnam
Grace Siew Wah Lim, Chief Financial Officer, KK Woman’s and Children’s Hospital, Singapore
Andres M.Licaros, Jr., President & Chief Executive Officer, Asian Hospital and Medical Center, Philippines
Michael Wong, CEO, Pantai Hospitals (Ayer Keroh), Malaysia
David Sun, Consultant of Neurosurgery, Prince of Wales Hospital, Hong Kong
Joe Hau, Director Corporate Services, Tan Tock Seng Hospital, Singapore
Alan Young, Head of IT, Canossa Hospital (Caritas), Hong Kong
Prof Kazuhiro Hara, President, Japanese Telemedicine and Telecare Association, Specially-appointed professor of Seto Inland Sea Regional Research Center, Kagawa University, Japan
Chan Woo Kuk, Center for Future Innovation, Advisory Specialist, Samsung Medical Center, Korea
http://www.tertiaryhospitalservices.com
Biopharma Production & Development Week 2015 Rita Barry
What’s New for 2015
- C-Level Panel: Cutting Edge Insights on China’s Growing Biotech Market
- China FDA Special Address
- 80+ Key Expert Speakers from Asia’s leading Pharma & Biotech
- 1 Joint Exhibition & Networking Area
- 4 Days of Expert Knowledge Sharing
- Revamped Program with New Special Focused Tracks & Sessions
Cell Line Development and Engineering 2015 Rita Barry
The 4th Annual Cell Line Development & Engineering Asia conference is a must attend event for you to get the latest updates and best practices in Cell Line Generation, Bioprocessing and Antibodies Development!
This exclusive forum is where industry experts will share lessons learned through case studies, strategic discussion groups and interactive roundtables to collectively collaborate and provide solutions to your most pressing challenges. Bring back new ideas to do better business!
4 Reasons Why You Must Attend this 2015
1. Update yourself with latest technologies to accelerate every stage of cell line development with maximum efficiency, quality and reduced cost
2. Enhance cell line generation in the early stages with best practices in transfection, optimizing cell culture media, and implement advancements in clone screening and selection techniques
3. Gain effective bioprocess control & optimization strategies, for efficient, safe and cost effective scale-up
4. Latest cutting edge updates on antibody development- novel screening strategies for target discovery, challenges in ADCs, engineering bispecifics and boosting efficacy in antibody therapeutics
http://www.celllineasia.com
What’s NEW in 2015’s program?
• More case studies on successful commercialization
• Insights on developing biosimilars under new CFDA guideline
• Emerging business models in regulated and developing markets
• New and timely topics on:
o Valuating biosimilars investments
o Successful technology transfer
o Key criteria in gaining approval
Also, NEW Expert Faculty includes:
Dr Shin Jae Chang, Vice President, Celltrion, Korea
Ira Jacobs, Global Oncology Lead, Biosimilars, Pfizer, US
Paul Thomas, Business Unit Head – Biosimilars, Biocon, India
Dr. Martina A. Sersch, Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.
Raj Kannan, Vice President, Commercial Head, Biosimilars, Merck, Switzerland
Huiguo (Forrest) Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China
Ko Chung Lin, Chief Executive Officer, PharmaEssentia Corporation, Taiwan
Wen Yong, Vice Director, Drug Research Institutes, Biopharmaceutical Institute, Jiangsu AoSaiKang Pharmaceutical Co Ltd, China
http://www.biosimilarsasia.com
“A key source of growth in biologics over the next several years will be Biomanufacturing” Ge Li, Chairman and CEO, Wuxi” <outsourcing-pharma.com,>
“Other issues with single-use include standardization of systems, the dependability to vendors, and the supply chain and waste management but if we can overcome extractables and leachables, we will eventually be able to scale up to many thousands of liters.” Jason Li, Senior Director, Downstream Processing, Genor Biopharma <biopharma-reporter.com,>
Industry experts will discuss these and more at the 5th Annual Biomanufacturing Conference in Grand Hyatt Shanghai, China on 19 – 22 May 2015 during IBC’s Biopharma Development & Production (BDP) Week.
As you know, pharma compliance is a critical issue, particularly in China. The Chinese government’s recent crackdowns on the business practices of various pharmaceutical companies have sent shockwaves throughout the industry and the price to pay for non-compliance is exceedingly high, with massive revenue losses and irreclaimable reputational damages
To address this pertinent issue, IBC Asia is convening the forthcoming Pharma Compliance Summit
(Mar 2015) in Shanghai, China. Set to be an informative and insightful event, this conference will prepare participants in dealing with the latest legal compliance landmines and equip them with an in-depth understanding of how to mitigate non- compliance risks at every part of the pharma value chain.
Top companies will share best practices of internal compliance programs and third party due diligence strategies; Gain these exclusive insights and incorporate them into their own company, reaping maximum benefits.
Your expert speaker faculty includes:
• Leon Wang, Vice President, AstraZeneca China
• Heike Deters, Head of Compliance, Bayer Healthcare China
• Dr Wang Xianlin, Member, Expert Advisory Group of Anti-Monopoly Commission, State Council People’s Republic of China
• Maija Burtmanis, Regional Legal & Compliance Director JAPAC, AbbVie
• Gareth Lee, General Counsel & Head of Compliance APAC, Allergan
• Cristopher Landrito, Regional Compliance Manager APAC, Merck
• David Shen, General Counsel & VP Legal, AstraZeneca China
• Dr Wu Ke, President, Shanghai BravoBio
• Alejandro Castro, Regional Audit Manager Asia Pacific, Novartis
• Linda Ling, Senior Healthcare Compliance Manager, OTC China, Johnson & Johnson
http://www.pharmacompliance-china.com
The inaugural Philippines Healthcare will focus on investment opportunities in the Philippines healthcare sector as well as examine the developments in healthcare plans and policies by government, market access opportunities for pharma and technology, new healthcare facility projects, upgrades and expansions and increasing efficiencies of existing facilities.
Philippines is currently focused on speeding up health facilities and upgrades, meeting the needs and growing demand for health specialists, training to ensure competency and quality of healthcare services and ensuring the availability of drugs throughout the country.
The conference will have discussions on policy and regulation updates, investment opportunities, projects and developments to strengthen Philippines healthcare infrastructure and delivery.
It will be held in Manila and will have representations from government, hospitals, insurance companies, pharma companies, health technology and medical device providers and other related stakeholders.
For 2015, we are going to hear NEW panel speakers from Indonesia Stock Exchange, Australia Stock Exchange, Philippine Stock Exchange, Tokyo Stock Exchange, Osaka Stock Exchange and Colombo Stock Exchange. Each of the exchanges will present a 10 minute update about their country on what are the new initiatives that have rolled out, how they address the needs of the private side, which infrastructure support the local regulatory body address in the short term vs. long term and the ASEAN trading link to ease cross border trading.
Not only that, we will answer key questions of the post trade industry including:
• Have Asian market participants been preparing for operational readiness as Dodd Frank, Emir and Basel 3 are being unrolled in Asia?
• Will T2S lead to a migration of all financial players to ISO 20022 in Europe?
• What are the impacts of Hong Kong Shanghai Stock Connect on Asia’s economy and the global financial markets?
• What is the impact on transaction funding and foreign exchange operations of moving from T+3 to T+2?
• Are CCPs all equal? Can we quantify the benefits of moving to a CCP?
• How is the buyside firm in Asia dealing with a collateral solution? Do the costs outweigh the benefits?
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
With cancer being the fastest growing healthcare priority in the pharmaceutical industry, IBC Asia announces the region's first ever strategic oncology conference focusing on clinical development and market access.
Download the brochure <link> now to identify new trends and opportunities in development and commercialization in the region.
ONCOLOGY ASIA focuses on the clinical development and effective market access for cancer drugs in Asia. It will cover strategies for developing oncology products and businesses from innovative pipelines, commercializing products, sales and marketing strategies to capture opportunities in Asia’s markets.
Featured sessions from top industry thought leaders:
Market Trends and Drivers in the Region
• James Garner, Head Unit Development Operations, Asia R&D, Sanofi, Singapore
What You Need to Know When Marketing Oncology Drugs
• Dr Paul Cornes, Clinical Oncologist, Bristol Oncology Centre, UK
Successful Market Access Strategies for Oncology Drugs
• Sameer Agarwal, Senior Vice President, Business Center Strategic
Marketing, Fresenius Kabi Deutschland GmbH, Germany
Clinical Engagement for Successful Oncology Products
• Dr Anish Desai, Director Medical & Clinical Affairs, Johnson & Johnson, India
http://www.oncologyasia.com
The offshore RMB market has evolved rapidly since 2010 and there have been periods of significant pricing dislocation between onshore and offshore forex and interest rate markets. Over the medium to long term, as the RMB exchange rate becomes more flexible, more products are traded in the offshore RMB market with growing liquidity, and capital account is gradually liberalized, the convergence trend in the pricing of onshore and offshore RMB asset markets is inevitable. <China Money Network, 28 July 2014)
The Value of RMB Currency in the Market, Liquidity & Risk will be discussed at IBC’s Offshore RMB Seminar (Parkroyal on Beach Road, Singapore * 27 November 2014) by these industry leaders:
Joe Ng, Head of Renminbi Payments Product Management - Asia Pacific, Global Transaction Banking, Deutsche Bank, Hong Kong
Update Speaker from Gladys, ICBC, Singapore
Motasim Iqbal, Head of Transaction Banking, Standard Chartered Bank, Singapore
Noritaka Akamatsu, Deputy Head, Office of Regional Economic Integration, Chair, Financial Sector Community of Practice, Asian Development Bank, Philippines
Other Key Topics Addressed Include:
• RMB Policy Liberalization
• Investing in RMB Capital Markets
• RMB Cross-Border Settlements
• Developing of Offshore RMB Operations
View more at http://www.offshorermbseminar.com
IBC’s Indonesia Healthcare conference brings together healthcare leaders to discuss evolving policies, opportunities for private healthcare investment, partnerships, projects and initiatives.
Key Conference Themes:
Updates on Regulation and the Road Towards Universal Healthcare Coverage
Hospital Management & Cutting Edge Healthcare Delivery Standards
Digital Marketing and Telehealth Solutions
Healthcare Infrastructure Projects, Investments & Development
Generics & Access to Medicine
Public-Private Partnerships & Collaboration
Why You Must Attend This Year’s Event
Understand the proactive steps to take by hospitals, pharmaceutical and insurance companies for the new Universal Healthcare Coverage policy
Discover partnerships and investment opportunities in Indonesia
Hear different case studies from major hospitals, insurance and pharmaceutical companies
Meet and exchange business cards with your peers during the networking sessions
Learn how to deliver safe and quality healthcare from other Asian countries
Medical Affairs teams in Asia’s diverse markets need to collaborate with R&D and understand the science, the business and the regulations. They need to constantly think strategically and communicate effectively.
• How can Medical Affairs teams be even more impactful in enhancing your company’s scientific reputation?
• How can you better communicate the value of your products to KOLs and Healthcare professionals?
• What makes a successful Medical Affairs team in Asia?
Get the answers and more at the 3rd MEDICAL AFFAIRS FORUM ASIA {link} - the region’s longest running strategy forum where leading medical affairs professionals share best practices, discuss common issues and learn from industry experts to enhance scientific reputation and better communicate the value of products to KOLs.
http://www.pharmaconasia.com/medical-affairs-forum-asia
PharmaCon - Pharmaceutical Congress Asia 2014 Rita Barry
The Leading Event Bringing 4 Successful Events Under 1 Roof!
The Pharmaceutical Congress Asia recognizes the importance of strong partnerships to drive innovation, development and winning products and services in Asia’s growing pharmaceutical industry. Packed with case studies from market leaders, four agendas will unite to create a hub of research, innovation, improved regulatory frameworks, best practice business, marketing and distribution models that will define Asia’s pharmaceutical future.
http://www.pharmaconasia.com
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
"𝑩𝑬𝑮𝑼𝑵 𝑾𝑰𝑻𝑯 𝑻𝑱 𝑰𝑺 𝑯𝑨𝑳𝑭 𝑫𝑶𝑵𝑬"
𝐓𝐉 𝐂𝐨𝐦𝐬 (𝐓𝐉 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
𝐓𝐉 𝐂𝐨𝐦𝐬 provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
⭐ 𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐬:
➢ 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
➢ SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
➢FreenBecky 1st Fan Meeting in Vietnam
➢CHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
➢ WOW K-Music Festival 2023
➢ Winner [CROSS] Tour in HCM
➢ Super Show 9 in HCM with Super Junior
➢ HCMC - Gyeongsangbuk-do Culture and Tourism Festival
➢ Korean Vietnam Partnership - Fair with LG
➢ Korean President visits Samsung Electronics R&D Center
➢ Vietnam Food Expo with Lotte Wellfood
"𝐄𝐯𝐞𝐫𝐲 𝐞𝐯𝐞𝐧𝐭 𝐢𝐬 𝐚 𝐬𝐭𝐨𝐫𝐲, 𝐚 𝐬𝐩𝐞𝐜𝐢𝐚𝐥 𝐣𝐨𝐮𝐫𝐧𝐞𝐲. 𝐖𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐫𝐭𝐥𝐲 𝐲𝐨𝐮 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐢𝐞𝐬."
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
1. International Marketing Partner:
www.generics-asia.com
Produced by:
Life
Sciences
Media Partners:
REGISTER TODAY! Tel: +65 6508 2401
Develop Competitive Strategies for Pricing,
Portfolio Management & Market Access
@IBCPharmaAsia
Supporting Associations:
Pre-Conference Workshop • 11 November 2013
Go-to-Market Innovation: Increasing
Awareness, Access & Margins
Post-Conference Workshop • 14 November 2013
Biosimilars Entry for Generic Companies
2 0 1 3
ASIA
Shanti Shamdasani
Regional Director,
Government Affairs –
ASEAN,
Johnson & Johnson
Jingyi Yu
Manager, Generics &
Biosimilar Business,
Strategy & Business
Development,
Pfizer
Jose Ochave
Senior Vice President,
Business Development,
Unilab
2013 Speaker Panel Includes:
NEW
NEW
NEW
Debbie Pangan
Corporate Affairs Director,
The Generics Pharmacy
Richard Lonsdale
Regional Relationship
Manager (Asia-Pacific),
AXA Healthcare
Management
NEW
NEW
Latest Hot Themes This Year
Market Access Opportunities
Universal Health Insurance Scheme Updates
Drug Pricing Challenges
Regulatory & Product Registration Updates
Branded Generics Launches
Biosimilars Market Entry
Drug-Delivery Device Partnerships
11 – 14 November 2013 | Marriott Hotel, Singapore
2. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
8th
ASIA2013
CONFERENCE DAY ONE
Tuesday, 12 November 2013
08:30 Registration & Welcome Coffee
09:00 Chairperson’s Opening Remarks
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals,
USA
GENERICS MARKET OUTLOOK & MARKET ACCESS
09:10 The Generics Game Plan: Tackling the Increasing Trend
Towards Commoditization of the Pharma Market
• International and regional Asia outlook for the generics market
• Tapping into Asia’s economic growth and how pharma can position
to take advantage of it
• How are innovators positioning themselves against generics
companies? Will price drive market share?
• What options are available for generics companies to differentiate
their products in an increasingly competitive & commoditized
market?
Palash Mitra, Partner, Mckinsey
09:45 Identifying the Roadblocks & Navigating Regulatory
Pathways to Maximize Market Access Across Asia
• What are the key factors influencing product registration across
Southeast Asia?
• Regulatory issues – bioequivalence standards for generics
• Addressing the option of local or regional manufacturing vs. import
from overseas
Ng Cheng Tiang, Director, Regulatory, Teva
Pharmaceutical Industries
10:20 Morning Refreshments
10:50 Achieving Regulatory Harmonization in ASEAN Countries
– An Industry Perspective
• Implications of regulatory harmonization in ASEAN – is it possible
to have one standard applied across different countries?
• Where are we with regards to the implementation readiness on
the harmonized product standard and conformance amongst
ASEAN members?
• Will harmonization change the generics game for industry?
• What is the industry’s current position and how to work closer
with regulators for ASEAN harmonization?
Herlina Aziz, HeadofRegulatory&Quality, Janssen Indonesia
11:25 The Evolving Market Access Landscape in Asia: From Self-
Paying to Reimbursed
• Changes to the healthcare system environment
• How will the changes impact originators and generic companies
• The rise of health consumers
• Moving beyond price focus towards value
Jeff Weisel, Managing Director, Celadon Health Ventures
12:00 Accessing Southeast Asia’s Highest Potential Countries:
Indonesia & Vietnam. How will their Universal Insurance
Coverage Impact the Pharma and Generics Market?
• Outlining the government’s plans for universal health insurance
coverage in Indonesia and Vietnam starting in 2014
• What role can international and local pharma companies now play
in the Indonesian & Vietnamese market especially with
implemented pricing for drugs on the EDL?
• How will branded generics or generic competitors be impacted
by the changes? Where are the opportunities?
• What and where are the opportunities for partnerships/JVs/M&A
for local and international players?
Shanti Shamdasani, Regional Director, Government Affairs –
ASEAN, Johnson & Johnson
12:35 Networking Lunch
14:00 Are Evergreening Strategies Futile in Asia?
• With India’s government ruling against Novartis, is it even worth
having a patent?
• What commercial implications are there for both originators and
generic players?
• What other lifecycle management options should MNCs consider
in order to fight off generics?
Dr Mandar Kodgule, Associate Vice President & Head, Global
IP & Strategic Planning, Wockhardt
ACCESSING NEW GLOBAL MARKETS
14:35 US&EuropeMarketEntryOpportunitiesforAsianGenerics
Players
• 3 years since the introduction of Obamacare in the US, will Asian
generics companies stand to benefit from greater generics usage
in the West?
• Latest regulatory and product registration guidelines
• With trends of increasing pricing pressures from governments,
how can pharma brace themselves to better react to this?
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals,
USA
15:00 Which Markets Should Local Generic Companies Expand
Into?
• Expand regionally or head west?
• Is MENA region still a contender?
• Why regional generic companies have not traditionally done well
outside their own market
• Key elements to consider before expansion internally and externally
Imtiaz Razzaq, Head, Business Development, Getz Pharma
15:45 Afternoon Refreshments
UTILIZING STRATEGIC PARTNERSHIPSTO BUILD MARKET
SHARE IN THE COMPETITIVE GENERICS MARKET
16:15 Pfizer’s Partnership with Hisun Pharma
• How Pfizer is building market share in the Chinese domestic market
• Critical factors in the selection of the product portfolio from each
partner
• Improving sales and marketing outreach
• Key success factors in the multi-cultural collaboration
• On-going alliance management to ensure a successful partnership
Jingyi Yu, Manager, Generics & Biosimilar Business, Strategy &
Business Development, Pfizer
16:50 How Strategic Partnerships Can Build Market Share
through Product Differentiation and Improved Market
Access
• Should MNCs partner with local companies?
• Is there a future for partnerships with regional players?
• Will supergenerics change the dynamics in Asia and if so, what
can each player (CROs, CMOs, originators & generic companies)
contribute to the partnership?
Moderator:
Julien de Salaberry, Managing Director, The Propell Group,
Former Head of Strategy & Business Development, Asia Pacific,
Merck & Co
Panellists:
Dr Fangchen Lee, Chairman, YungShin Group
Dr Azizi Ayob, Medical/Scientific Director,
Questra Clinical Research
17:35 Chairperson’s Remarks and End of Conference Day One
PANELDISCUSSION
3. 09:00 Chairperson’s Opening Remarks & Recap
Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals,
USA
EXPANDING GLOBAL PRESENCE & PRODUCT
PORTFOLIO TO REAP GREATER COMMERCIAL SUCCESS
09:20 Considerations for a Regional Generic Company Entering
into Biosimilars
• Assessing the possible product pipeline
• What are the opportunities and challenges of entry into biosimilars?
• Key factors to consider before entry
• Should companies purchase or invest in their own expansion?
Dr Milind Sabnis, Principal Consultant, Healthcare,
Frost & Sullivan
09:55 Investing in Supergenerics in order to Increase Portfolio
Profits
• What is the opportunity in supergenerics?
• Changing dosages vs changing delivery devices – which molecules
to consider before making the decision
• Key considerations before investing in supergenerics
• Should the local generic company in-house or outsource parts of
the development?
Dr Lida Kalantzi, Pharmacist, Product Evaluation & Design,
R&D, Pharmathen
10:30 Morning Refreshments
11:00 Enhancing Product Differentiation through Novel Drug
Delivery Technology
• Understanding the strategic alliance between drugs and delivery
devices
• Assessing Asia’s acceptance of various alternatives in delivery
methods
• How can device companies engage with local generic companies
to grow their current portfolio into supergenerics?
For speaker updates, please visit www.generics-asia.com
MARKETING & DISTRIBUTION
11:35 Creating the Right Generics Brand, Beyond Cost
• The Asian stakeholders' perception towards generics
• How can generic companies create the right mindset to foster
greater demand
• Key elements in creating a generic ‘brand’
• Can innovators still win within the generics space?
Graeme Read, EVP, Chief Strategy Officer, McCann Health
12:05 Networking Lunch
13:15 Raising Brand Awareness and Consumer Choice the
RiteMed Way
• Creating a uni-brand for OTC, ethical and innovative products
• A cost effective method of using media and advertising to promote
a corporate brand
• Changing how medication is bought: Switchability occurring at
patient level
Jose Ochave, Senior Vice President, Business Development,
Unilab
8th
ASIA2013
CONFERENCE DAY TWO
Wednesday, 13 November 2013
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
13:50 Gaining a Greater Perspective from Pharmacy
• How are prescribers differentiating between the various generic
options?
• Is it easy to obtain switchability?
• What tools are required by the marketing and sales teams to build
the client relationship with prescribers?
• Building the pharma distribution network and relationship
• What are the areas of interest in Asia?
• How to work with pharma to gain greater pricing differential
• Key points pharma needs to be aware of when dealing with payers
Debbie Pangan, Corporate Affairs Director,
The Generics Pharmacy
14:25 Insights into the Payer’s Perception of Generics
• What are the areas of interest due to under-coverage in Asia?
• What are the different models of insurance coverage in healthcare
available in Asia?
• Key points pharma needs to be aware of when dealing with payers
Richard Lonsdale, RegionalRelationshipManager(Asia-Pacific),
AXA Healthcare Management
15:00 Afternoon Refreshments
15:30 Distribution of Products to Remote Parts of Asia Ensuring
Increase in Patient Access
• Key elements in tropical Asia to consider in cold chain management
• What are the major logistical challenges?
• A variety of services – what do pharma look for in choosing a
partner
For Speaker updates, please visit www.generics-asia.com
16:05 How can Companies Stay Ahead in the Branded
Generics Race
• What are the perception differences of quality, price and safety in
Asia?
• Should companies invest in branding and charge a higher price
or compete in offering the lowest possible?
• Tailoring launch strategies in Asia to gain maximum exposure
Moderator:
Viren Mahurkar, Managing Director, HitchinRock Advisors,
Former Senior Vice President, Global Business Development,
Wockhardt
Panelists:
Thomas Runkel, Vice President, Asia Pacific, Actavis
Khai Meng Ang, Vice President, Asia, Hospira
Cheah Ming Loong, General Manager, Ethical Division,
Kotra Pharma
Dr Imran Khalid , Director, Marketing & Sales, Getz Pharma
16:50 Chairperson’s Closing Remarks and End of Conference
CLOSINGPANEL
“Very informative, well organized and
enlightening”
~ Krystal, Eisai Malaysia
“Event was very informative and I got
connected with many new people”
~ Mahmood, Getz Pharma
4. Richard DiCicco, Chairman, Harvest Moon
Pharmaceuticals USA, Inc
Rich co-founded in 2007, with a proven pipeline of products
developed since 1984, Harvest Moon Pharmaceutical (HMP)
develops and licenses-out to the trade, worldwide, complex
generic drug products, copy bio products and biosimilars.
Rich is a member of the Editorial Board of the Journal of
Generic Medicines, a member of the Licensing Executives Society and is
widely published in generics and biosimilars.
Dr Janet M McNicholas, Partner, Jones Day
Janet has headed the biotechnology patent practice at
McAndrew, Held and Malloy, the Life Sciences Patent Group
of Cooley Godward in Palo Alto and served as patent counsel
for XOMA, a biotechnology company known as a leader in
the development of therapeutic antibodies. Prior to practicing
law, Janet conducted research in immunology, molecular
biology, biochemistry and genetics at Stanford University and at the California
Institute of Technology through a post-doctoral fellowship.
8th
ASIA2013 WORKSHOPS
REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
This half-day workshop will run from 13:30 to 17:00, with a mid-afternoon break. Registration begins 30 minutes before the workshop commences.
Pre-Conference Afternoon Workshop A l 11 November 2013
Go-to-Market Innovation: Increasing Awareness, Access & Margins
Workshop Objectives:
It is not the availability of drugs that is the issue in solving the Asia
disease burden. In fact, pharmaceutical products are readily available!
It is the immature healthcare infrastructure in these markets that
prevents available products reaching those in need. Overcoming these
infrastructure limitations and challenges requires drug manufacturers
to adapt or re-invent their business model.
The Go-to-Market Innovation workshop aims to address these and
other challenges in the pharmaceutical industry by going beyond the
product and taking a go-to-market perspective.
Looking at your existing and upcoming products, how could you
innovate the way these are brought to the market, thereby improving
awareness, access, margins and social responsibility? Through cross
industry examples, practical frameworks and real life case studies, the
participants will generate, discuss and assess innovative ideas to
change the dynamics of doing business in Asia.
Workshop Agenda:
Participants are encouraged to bring a list of emerging market
challenges they face and/or foresee to facilitate discussion
Share & discuss go-to-market developments and challenges in
Asia
How to innovate your way of doing business and go beyond
product differentiation
Broaden your thinking: learn from other industries
Break outs to generate innovative go-to-market ideas based on
real case studies and develop the high level business model / key
elements
Sharing of go-to-market ideas/business models and learnings
from breakouts session
Discussion on applicability and way forward for the identified go-
to-market innovations
Led By:
Julien de Salaberry, Managing Director, The Propell
Group, FormerHeadofStrategy&BusinessDevelopment,
Asia Pacific, Merck & Co
Julien is an experienced regional head and GM – a global
leader with a cross cultural mindset. He has had 15+ years in
healthcare with leading brands including Eli Lilly, Boston
Scientific, Baxter, GSK, Merck&Co.. Currently, Julien is an
advisor to startups and incubators in healthcare and technology in emerging
high growth markets.
Specialties: Business Model Strategy & Design, Commercial Innovation,
Inorganic & Organic Growth, Mergers & Acquisitions / Joint Ventures,
Turnaround, Multicultural Team Leadership
Nynke Kinderman, Innovation Consultant
Nynke is an experienced business innovation and market
development consultant with strong expertise in the field of
new business models. She possess a cross industry
perspective due to driving the go-to-market for leading MNCs
in amongst others financial services, utilities, consumer goods
and automotive.
Specialties: Business Model Innovation and Design, Market Entry, Investment
analysis, Training & Development on Innovation Capabilities
Post-Conference Full-Day Workshop B l 14 November 2013
Biosimilars Entry for Generic Companies
An overview of the challenges and opportunities in the biosimilars
market
Selecting country of origin in certain market tenders to facilitate
registration
Impact of second generation molecules being launched prior to
availability of first generation biosimilars
How important is interchangeability and substitution for the
second wave of biosimilars?
• In chronic indications of RA, Psoriasis and Crohns?
• In oncology indications?
What future molecules should be considered for development
and where could there be synergies?
What are the various market entry/launch strategies in
pharmerging Asia?
Gauging originators’ response to biosimilars
Litigation?
Authorized biosimilars?
Strategic pricing?
Life cycle management strategies?
Implications of such actions in MENA, LATAM and APAC emerging
markets
What is the recommended legal due-diligence needed before
entry into pharmerging countries?
Whataretheessentialsinordertosuccessfullydevelopandlaunch
biosimilars?
This full-day workshop will run from 09:00-17:00, with mid-morning and afternoon breaks and lunch. Registration begins 30 minutes before the
workshop commences.
Led By:
5. REGISTER TODAY! +65 6508 2401 register@ibcasia.com.sg www.generics-asia.com
Countries Represented
• Do you find difficulty in reaching senior decision makers and
successfully stimulating interest for your services?
• Are you trying to raise awareness of the value of your company’s
expertise and services?
• Or are you finding it difficult to differentiate your company from
your competition?
Who You’ll Meet
■ Regulatory Authorities(government) &
Ministry of Health 2%
■ Generic & Biosimilars Companies 45%
■ Innovator Pharma Companies 35%
■ Drug Delivery Companies 5%
■ Contract Research Organizations /
Analytical Labs 2%
■ Contract Manufacturing Organizations 5%
■ API companies 2%
■ Pharma Wholesalers & Distributors 2%
■ Others 2%
• Business Development & Strategy
• Government Affairs
• Marketing
• IP /Legal Counsel
• Sales
• Regulatory Affairs
• Product Development
• Strategy Planning & Development
• Licensing
• Commercial
• Formulations
• Procurement / Sourcing
• External Manufacturing
• Clinical Trials
• Collaborative Research
• CMO Account Management
• Quality Assurance
• Technology Transfer
CEOs, CSOs, Managing Directors,
Director, VP, Head of
Sample Past Attending Companies
ACTAVIS • ASTRAZENECA • BAYER • BECTON DICKINSON • BOEHRINGER INGELHEIM
GMBH • CCM PHARMACEUTICALS • CENTRUM CAPITAL • DR REDDY’S LABORATORIES
• DRUG HOUSES OF AUSTRALIA • EISAI • ELI LILLY • GENENTECH • GETZ PHARMA •
GLAXOSMITHKLINE • HANWHA CHEMICAL • HOSPIRA • HOVID • JCR PHARMACEUTICALS
• MYLAN • MERCK • NIPPON KAYAKU • NORTH CHINA PHARMACEUTICAL GROUP
CORPORATION • PFIZER • PHARMANIAGA • PT DEXA MEDICA • PT KALBE • RANBAXY
•SANDOZ•SANOFI-AVENTIS•SAKEDA•UNITEDLABORATORIESINC•USV•WOCKHARDT
• ZUELLIG PHARMA • ZYDUS CADILA HEALTHCARE
North Asia 12%
China 3%
Taiwan 6%
Hong Kong 4%
Indonesia 10%
Singapore 35%
Thailand 8%
Malaysia 15%
India 8%
What you need is a branding opportunity at this event! Increase your
reach through our extensive marketing campaign, targeted at your
qualified business audience.
For information about placing your brand & profile top-of-mind to
key buyers, contact Yvonne Leong, Business Development Manager
on Tel: + 65 6508 2489 / yvonne.leong@ibcasia.com.sg
Sponsorship Opportunities
Raise awareness for your services available to Asian pharmaceuticals!
11 – 14 November 2013
Sheraton Towers, Singapore
What’s New This Year
The emergence of greater national insurance coverage
across Asia
Lifecycle management & post-pay-for-delay evergreening
strategies
Strategic partnerships for growth
Challenges and opportunities in supergenerics & biosimilars
Branding strategies that deliver results
With austerity measures being put in place globally, greater
emphasis on generics comes to light in terms of cost savings.
In Asia, countries are gearing towards greater regulatory
harmonization and universal health coverage. IBC’s 8th
Generics Asia 2013, the longest running conference bringing
together East and West, innovators and generics companies,
will discuss strategies and commercial opportunities from the
generic spending boom!
Why You Need To Attend in 2013
Annual global spending on medicines will reach nearly $1.2 trillion in 2016
Global generic spending will increase from $242Bn in 2012 to $400-430Bn by 2016 – an increase of 77%
*IMS Health 2013
Develop Competitive Strategies for Pricing, Portfolio
Management & Market Access
2 0 1 3
ASIA
8th
6. ENJOY SUBSTANTIAL SAVINGS WITH
OUR MULTIPLE BOOKING DISCOUNT!
Early Bird Rate
Register & pay on or
before 6 Sep 2013
FEE PER DELEGATE
Special Rate
Register & pay on or
before 4 Oct 2013
Group Rate
(3 or more delegates)
Normal Rate
Register & pay after
4 Oct 2013
REGISTER NOW! FAX BACK TO +65 6508 2407
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
This label contains your priority booking code. To expedite registration, please do not remove label. If you have
already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not
available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
6 EASY WAYS TO REGISTER
Email
register@ibcasia.com.sg
Customer Service Hotline
+65 6508 2401
Fax
+65 6508 2407
Web
www.generics-asia.com
❑ Yes! I/We will attend the 8th Generics Asia 2013 | 11 – 14 November 2013, Marriott Hotel, Singapore
REGNO.200108203N
Who is Head of your Department?
Who is Head of Training?
Company Information
Company Name:
Address:
Main Business/Activity:
Postal Code:
8th Generics Asia 2013
❑ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
RESERVE YOUR PLACE TODAY!
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at
www.generics-asia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name and
details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest
confidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46227
Payment Method (Please tick:) ❑ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
❑ I am paying by bank transfer (copy attached)
❑ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
Payment must be received 10 business days prior to the event. To
take advantage of discounts with an expiry date, registration and
payment must be received by the cut-off date.
• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:
IBC Asia (S) Pte Ltd
A/C No.:147-059513-001 (S$)
A/C No.:260-457866-178 (US$)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building
Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).
The best way to pay by credit card is through our secure portal
built into the website. To pay by phone please indicate the
contact name and details below and our Customer Services
Team will call within 24 hours to take payment. Please do not
send credit card information by email.
SAVE WITH THE
EARLY BIRD &
SPECIAL RATES!
❑ 2 Day Conference only
If undelivered, please return to:
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408
Please photocopy for additional delegates
FREE
GROUP DISCOUNT
Delegate 1 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 2 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 3 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 4 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
SGD 2,595 SGD 2,795 SGD 2,995 SGD 2,495
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee
stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
• A 7% Goods & Services Tax (GST) is applicable to all Singapore based companies for Singapore venue.
The personal information entered during your registration/order, or
provided by you, will be held on a database and may be shared
with companies in the Informa Group in the UK and internationally.
Occasionally, your details may be obtained from or shared with
external companies who wish to communicate with you offers
related to your business activities. If you do not wish your details
to be used for this purpose, please contact our Database Department
at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or Fax:
+65 6508 2408.
Should you be unable to attend, a substitute delegate is welcome
at no extra charge. Cancellations must be received in writing at
least 10 business days before the start of the event, to receive a
refund less 10% processing fee per registration. The company
regrets that no refund will be made available for cancellation
notifications received less than 10 business days before the event.
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges are
to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice, cheque
or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to ensure
all details are as published. IBC assumes no further liability or
obligation, beyond the refund of the paid registration fee, in the
event of postponement or cancellation by IBC.
SGD 3,695 SGD 3,895 SGD 4,095 SGD 3,595❑ 3.5 Day Package:
Conference + Workshops A + B
MAIL the attached registration form with your
cheque to IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset
#10-06, Singapore 238164
Scan the QR Code
with your smartphone
and register today
SGD 3,395 SGD 3,595 SGD 3,795 SGD 3,295❑ 3 Day Package:
Conference + Workshop B
SGD 2,995 SGD 3,195 SGD 3,395 SGD 2,895❑ 2.5 Day Package:
Conference + Workshop A
GROUP BONUS – Register 3 Delegates from the same company and the 4th Delegate attends FREE!
Marriott Hotel, Singapore
320 Orchard Road, Singapore 238865
DID: +65 6735 5800
Fax: +65 6735 9800
Contact Person: Peiqin Chua
Email: peiqin.chua@marriott.com